Currently out of the existing stock ratings of Josh Schimmer, 84 are a BUY (85.71%), 13 are a HOLD (13.27%), 1 are a SELL (1.02%).

Josh Schimmer

Work Performance Price Targets & Ratings Chart

Analyst Josh Schimmer works at CANTOR FITZGERALD with a stock forecast success ratio of 50.96% fulfilled within 245.48 days on average.

Josh Schimmer’s has documented 539 price targets and ratings displayed on 31 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on LBPH, Longboard Pharmaceuticals at 13-Mar-2024.

Wall Street Analyst Josh Schimmer

Analyst best performing recommendations are on SPRO (SPERO THERAPEUTICS).
The best stock recommendation documented was for SPRO (SPERO THERAPEUTICS) at 5/4/2022. The price target of $2 was fulfilled within 2 days with a profit of $0.25 (14.29%) receiving and performance score of 71.43.

Average potential price target upside

of $62.54 (21.92%) on BIIB (BIOGEN).
of $62.48 (52.23%) on AMGN (AMGEN).
of $54.69 (48.82%) on KRYS (KRYSTAL BIOTECH).

ALXN Alexion Pharmaceuticals BLU BELLUS Health . DICE Dice Molecules Holdings LLC FDMT 4D Molecular Therapeutics HRTX Heron Therapeuti INSM Insmed IONS Ionis Pharmaceuticals MDGL Madrigal Pharmaceuticals REGN Regeneron Pharmaceuticals RGNX Regenxbio SPRO Spero Therapeutics VTYX Ventyx Biosciences CABA Cabaletta Bio ICVX Icosavax INBX Inhibrx ADMS Adamas Pharmaceuticals GOSS Gossamer Bio RNA Avidity Biosciences ZYME Zymeworks . Common Stock AKRO Akero Therapeutics BBIO BridgeBio Pharma CRNX Crinetics Pharmaceuticals ERAS Erasca INCY yte KDNY Chinook Therapeutics KRYS Krystal Biotech ASND Ascendis Pharma AS PMVP Pmv Pharmaceuticals LBPH Longboard Pharmaceuticals MIRM Mirum Pharmaceuticals XENE Xenon Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hartaj Singh (OPPENHEIMER)